Product Information
BEPOTASTINE 1.5% EYE DROP is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $10.4866 per ML under NDC 00378705535. Its NADAC has been published 268 times since Aug 18, 2021.
FDA first approved this application on Mar 18, 2019. Its Orange Book therapeutic-equivalence code is AT.
Strength
15 mg/mL
Manufacturer
Mylan Pharmaceuticals Inc.NDC
00378705535
Classification
Generic
Dosage Form
SOLUTION/ DROPS
Route
OPHTHALMIC
Effective Date
9/23/2026
Active Ingredients
BEPOTASTINE BESILATEApproval Type
Generic (ANDA)
FDA Application
ANDA206220FDA Approved
3/18/2019
TE Code
AT
On Market Since
5/28/2021
Pharmacological Classes
Price Statistics
The NADAC for BEPOTASTINE 1.5% EYE DROP has been published 268 times since Aug 18, 2021, and over the history we have for it it has declined 72.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $10.4866 per ML |
|---|---|
| All-time high | $38.6198 (Dec 15, 2021) |
| All-time low | $10.4866 (Sep 23, 2026) |
| 52-week high | $14.6492 |
| 52-week low | $10.4866 |
| Median price | $18.8868 |
| Average price | $20.4874 |
| Largest weekly change | +49.6% (Nov 20, 2024) |
| Weeks tracked | 268 |
| Tracking since | Aug 18, 2021 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 21% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Bepotastine Besilate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Histamine-1 Receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BEPOTASTINE 1.5% EYE DROP?
The current National Average Drug Acquisition Cost (NADAC) for BEPOTASTINE 1.5% EYE DROP, manufactured by Mylan Pharmaceuticals Inc., is $10.4866 per ML (NDC 00378705535), effective Sep 30, 2026.
How has the price of BEPOTASTINE 1.5% EYE DROP changed over time?
Over the history we have for it, the NADAC for BEPOTASTINE 1.5% EYE DROP has declined 72.6%. It has been tracked across 268 weekly CMS publications since Aug 18, 2021.
What are the highest and lowest recorded NADAC prices for BEPOTASTINE 1.5% EYE DROP?
Since Aug 18, 2021, the NADAC for BEPOTASTINE 1.5% EYE DROP has ranged from a low of $10.4866 (Sep 23, 2026) to a high of $38.6198 (Dec 15, 2021), with a median of $18.8868 per ML.
Are there cheaper alternatives to BEPOTASTINE 1.5% EYE DROP?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, BEPOTASTINE 1.5% EYE DROP, is $8.2857 per ML — about 21% below BEPOTASTINE 1.5% EYE DROP.
Who manufactures BEPOTASTINE 1.5% EYE DROP?
BEPOTASTINE 1.5% EYE DROP (NDC 00378705535) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.